Inhibition of Leucocyte Migration in Man by the Agarose Plate Technique Using Protein Purified Derivatives (Ppd) From Three Different Sources

Passaleva, A; Forti, Alec; Ricci, M

doi:10.1111/j.1398-9995.1974.tb01649.x

Cited by 6 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…His results were confirmed by several other investigators [17][18][19][20][21]. We decided t o include lymphocyte transformation in vitro (LTT) in our studies on the possible relationship between the methods generally in use t o demonstrate cellular immunity (CMI) [22,23].…”

Section: Introductionmentioning

confidence: 52%

Correlation of PPD and BCG‐induced leukocyte migration inhibition, delayed cutaneous hypersensitivity, lymphocyte transformation in vitro and humoral antibodies to PPD in man

Fleer

et al. 1976

Eur J Immunol

View full text Add to dashboard Cite

In a study of healthy human individuals a complete lack of correlation between the results of the agarose leukocyte migration inhibition (LMI) test, using purified protein derivative (of tuberculin) (PPD) and Bacillus Calmette Guérin (BCG) as antigens, and delayed cutaneous hypersensitivity and lymphocyte transformation in vitro to PPD was found. There was a reasonable correlation between PPD- and BCG-induced LMI. Antibodies to PPD proved to have no influence on PPD-induced LMI. Purified polymorphonuclear leukocytes, whether derived from donors sensitive to PPD in the agarose LMI test or from nonsensitive donors, did not show migration inhibition to PPD. It was concluded that polymorphonuclear leukocytes and lymphocytes need to be present simultaneously for migration inhibition of peripheral blood leukocytes by PPD. Furthermore, because a consistent relation with conventional parameters of cell-mediated immunity was lacking, it is doubtful whether the agarose LMI test can be considered as an alternative parameter of this kind of immunity.

show abstract

Section: Introductionmentioning

confidence: 52%

Correlation of PPD and BCG‐induced leukocyte migration inhibition, delayed cutaneous hypersensitivity, lymphocyte transformation in vitro and humoral antibodies to PPD in man

Fleer

et al. 1976

Eur J Immunol

View full text Add to dashboard Cite

show abstract

Cell-Mediated Immunity In Vitro in Atopic Dermatitis

Horsmanheimo¹

1979

Arch Dermatol

View full text Add to dashboard Cite

In vitro reaction of cancer patients and others to Bacillus Calmette‐Guérin

Todd

Chen

et al. 1980

Intl Journal of Cancer

View full text Add to dashboard Cite

We examined the in vitro reaction of leukocytes from 71 cancer patients and 121 control donors (disease-free individuals or patients with non-malignant non-debilitating conditions) against Bacillus Calmette-Guérin using a one-stage capillary leukocyte migration assay. The proportion of reactive cancer patients and control donors increased with increasing BCG concentration, but the proportion of patients who reacted was less than that of control donors at all concentrations of BCG. As cancer stage advanced and the volume of clinically detectable tumor increased, the proportion of reactive patients decreased. There was a small age-related decline in reactivity in the control population. The results of simultaneous in vitro tests and Mantoux reactions were concurrent in a majority of normal individuals so tested.

show abstract

Inhibition of Leucocyte Migration in Man by the Agarose Plate Technique Using Protein Purified Derivatives (Ppd) From Three Different Sources

Cited by 6 publications

References 19 publications

Correlation of PPD and BCG‐induced leukocyte migration inhibition, delayed cutaneous hypersensitivity, lymphocyte transformation in vitro and humoral antibodies to PPD in man

Correlation of PPD and BCG‐induced leukocyte migration inhibition, delayed cutaneous hypersensitivity, lymphocyte transformation in vitro and humoral antibodies to PPD in man

Cell-Mediated Immunity In Vitro in Atopic Dermatitis

In vitro reaction of cancer patients and others to Bacillus Calmette‐Guérin

Contact Info

Product

Resources

About